Ultragenyx Pharmaceutical Inc. (RARE) and Otonomy Inc. (NASDAQ:OTIC) Contrasting side by side

This is a contrast between Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Otonomy Inc. (NASDAQ:OTIC) based on their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ultragenyx Pharmaceutical Inc. 51.49M 75.72 197.61M -3.90 0.00
Otonomy Inc. N/A 115.33 50.37M -1.85 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Ultragenyx Pharmaceutical Inc. and Otonomy Inc.


Table 2 provides us the return on equity, return on assets and net margins of both companies.

Net Margins Return on Equity Return on Assets
Ultragenyx Pharmaceutical Inc. -383.78% -29.3% -25.4%
Otonomy Inc. 0.00% -54.2% -49.5%

Volatility & Risk

A 2.2 beta indicates that Ultragenyx Pharmaceutical Inc. is 120.00% more volatile compared to Standard and Poor’s 500. In other hand, Otonomy Inc. has beta of 2.49 which is 149.00% more volatile than Standard and Poor’s 500.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for Ultragenyx Pharmaceutical Inc. and Otonomy Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Ultragenyx Pharmaceutical Inc. 0 3 6 2.67
Otonomy Inc. 0 0 1 3.00

The upside potential is 3.68% for Ultragenyx Pharmaceutical Inc. with average price target of $70.78. Competitively Otonomy Inc. has a consensus price target of $5, with potential upside of 78.57%. Based on the data delivered earlier, Otonomy Inc. is looking more favorable than Ultragenyx Pharmaceutical Inc., analysts view.

Institutional & Insider Ownership

The shares of both Ultragenyx Pharmaceutical Inc. and Otonomy Inc. are owned by institutional investors at 0% and 66.1% respectively. Insiders held roughly 0.4% of Ultragenyx Pharmaceutical Inc.’s shares. Insiders Comparatively, held 0.29% of Otonomy Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Ultragenyx Pharmaceutical Inc. 4.21% 33.9% 19.9% -21.29% 36.36% 51.89%
Otonomy Inc. 8.22% 16.75% 1.72% -22.3% -58.05% 28.11%

For the past year Ultragenyx Pharmaceutical Inc. was more bullish than Otonomy Inc.


Otonomy Inc. beats on 7 of the 11 factors Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. Its biologics product candidates also comprise recombinant human beta -glucuronidase (rhGUS), an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis. The company is also developing range of small-molecule product candidates, such as UX007, a substrate replacement therapy that is in Phase II study for patients with fatty acid oxidation disorders, as well as for patients with glucose transporter type-1 deficiency syndrome; and aceneuramic acid extended-release (Ace-ER), an oral formulation of sialic acid, which is in Phase III extension study to treat GNE myopathy. It has collaboration and license agreements with Arcturus Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Kyowa Hakko Kirin Co. Ltd.; Saint Louis University; Baylor Research Institute; Nobelpharma Co., Ltd.; Alcami Corporation; HIBM Research Group; and St. Jude ChildrenÂ’s Research Hospital. The company was founded in 2010 and is headquartered in Novato, California.

Otonomy, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. OTIPRIO has also completed a Phase III clinical trial for treating swimmer’s ear and a Phase II clinical trial for treating acute otitis media with tubes. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière’s disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.